Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — Technical Presentation (August 2026)
21 slides from Silence Therapeutics's technical presentation, Aug 10, 2026
Slide 1: SANRECO Phase 2 Topline Results in Polycythemia Vera
SANRECO Phase 2 Topline Results in Polycythemia Vera August 10, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation
Slide 3: Introduction
Introduction Iain Ross, Chairman and Interim Principal Executive Officer
Slide 4: Silence – siRNA Platform Company with Compelling Clinical Data Across Multiple Programs
Silence – siRNA Platform Company with Compelling Clinical Data Across Multiple Programs FRANCHISE GOLD PLATFORM CLINICAL RESULTS OPPORTUNITY ‒ Proven GalNAc siRNA ‒ Four clinical-stage assets ‒ Divesiran: first-in-class siRNA technology with broad utility targeting large unmet needs for PV ‒ Potent,
Slide 5: PV: Large Unmet Need and Proven Market Value Create Significant Upside
PV: Large Unmet Need and Proven Market Value Create Significant Upside for a Best-in-Class Therapy Large Underserved Current Options are Compelling Product Population 2-5 Limited 2-5 Profile ‒ Many PV patients remain ‒ Limitations in efficacy, safety ‒ Robust efficacy phlebotomy-dependent and tolera
Slide 6: SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients
SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients Efficacy Endpoints Safety Endpoints Infrequent Dosing 6
Slide 7: SANRECO Phase 2 Topline Results
SANRECO Phase 2 Topline Results Steven Romano, MD, Chief R&D Officer
Slide 8: Divesiran Clinical Development Program
Divesiran Clinical Development Program Polycythemia Vera • PV is a rare myeloproliferative neoplasm characterized by excessive production of red blood cells ‒ Elevated hematocrit (Hct) >45% ‒ Primary treatment goal is to maintain Hct <45% Preclinical Phase I Phase II Key Milestones Polycythemia Vera
Slide 9: Phase 2 SANRECO Study is a Global Trial: 9 Countries / 4 Continents
Phase 2 SANRECO Study is a Global Trial: 9 Countries / 4 Continents 9
Slide 10: Phase 2 SANRECO Study: Clinical Study Design
Phase 2 SANRECO Study: Clinical Study Design 10
Slide 11: SANRECO Phase 2 Study Overview
SANRECO Phase 2 Study Overview • 36-week, placebo-controlled, double-blind period followed by a 3-year, double-blind and open-label Design extension period evaluating divesiran in 48 phlebotomy-dependent PV patients • PV diagnosis Key Inclusion • At least 3 phlebotomies in the last 6 months or 5 in
Slide 12: SANRECO: Primary Efficacy Endpoint - Response Rate
SANRECO: Primary Efficacy Endpoint - Response Rate The primary endpoint was met: • Significantly higher proportion of clinical responders among the divesiran treated PV patients (88%) compared to those who received placebo (19%) during weeks 18-36; p<0.0001 • Placebo adjusted response rate = 69% Res
Slide 13: SANRECO: Primary Efficacy Endpoint by Dose Groups
SANRECO: Primary Efficacy Endpoint by Dose Groups Responders (week 18 through week 36) 100 93.8% 81.3% Placebo n=16 80 Percent of Patients with Response Divesiran Q12W n=16 Divesiran Q6W n=16 60 40 20 18.8% 0 Note: Response is defined as HCT remaining below 45% and no phlebotomies received during we
Slide 14: SANRECO: Response Rate Sensitivity Analysis (n=40)
SANRECO: Response Rate Sensitivity Analysis (n=40)* • Significantly higher proportion of clinical responders among the divesiran treated PV patients (89%) compared to those who received placebo (8%) during weeks 18-36; p<0.0001 • Placebo adjusted response rate = 81% Responders (week 18 through week
Slide 15: SANRECO: Key Secondary Endpoint - Phlebotomy Rate
SANRECO: Key Secondary Endpoint - Phlebotomy Rate • Mean number of phlebotomies in the divesiran arm was 0.2 compared to 2.1 phlebotomies in the placebo arm during weeks 0-36 (p<0.0001) % of Patients Who received No Phlebotomies From Baseline through week 36 100 90.6% Placebo n=16 80 Divesiran n=32
Slide 16: SANRECO: Other Secondary Endpoints
SANRECO: Other Secondary Endpoints • Divesiran groups also showed improvements in: ‒ Hematocrit control ‒ Iron markers, including ferritin ‒ Patient reported outcomes using MPN-SAF Total Symptom Score (MPN-SAF TSS) 16
Slide 17: Summary of Adverse Events (Weeks 0-36)
Summary of Adverse Events (Weeks 0-36) • Divesiran was generally well tolerated • Safety profile was in line with previous divesiran trials; no new safety findings • Injection site reactions were infrequent and self-limiting • There were two investigator reported grade 1 anemia adverse event cases 1
Slide 18: Next Steps
Next Steps • Phase 2 SANRECO full results ‒ Submitted abstract to ASH Congress (Dec 12-15, New Orleans) • End of Phase 2 meeting by year end • Initiate Phase 3 study in 1H 2027 18
Slide 19: SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients
SANRECO Results Support Potential Best-in-Class Treatment for Phlebotomy-Dependent PV Patients Efficacy Endpoints Safety Endpoints Infrequent Dosing ‒ Primary endpoint was ‒ Well tolerated with no ‒ Comparable efficacy and met at both Q6W and new safety findings safety results across Q12W intervals
Slide 20: Q&A
Q&A THERAPEUTICS
Slide 21: Thank You!
3 SILENCE THERAPEUTICS * THANK YOU!
Silence Therapeutics — Technical Presentation (August 2026) on 6ix